Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
in fact they may release it after 430pm today. the vwap of GenM is below 2.7 for the past 4 trading days. even if tomorrow GenM rally to 2.85, it won't affect their payout as the vwap would be below 2.80. hence they pay nothing for their call warrant.
GenM has pulled back up by more than 10% from the triple bottom and it broke above the mid term downtrend trendline that started in Oct'21; same time as GenM's bear market rally top back then. Trends take time to build if you will. Perhaps we should be seeing some dull rounding turns higher.
its the mashpee wampanoag tribe integrated resort project which was halted previously resulted in 1.8bil impairment for GenM. The US court has granted the rights to the land to the tribe. And the tribe has requested meeting with the Taunton Council to review the project. If the project is revived in due time, there's opportunity for impairment reversal for the 1.8bil :)
It can be a worthwhile wait for both the impairment reversal and Miami land sale; estimated 30 cents per share impact and 75 cents per share respectively.
Lets not forget that GenM has a parent company by the name of Genting :) GenM's revenue contribution to Genting is significant; more than 30% - Malaysia, US, UK, Egypt. I am pretty sure when the needs arises, Genting will step up to provide the financial assistance :)
Btw, not to worry too much about the "blocking". It has nothing to do with warrants expiring. I believed it has to do with the shorts covering and Dec window dressing :) For now, positive prospects and recent IB ratings (TA, Pbbank, Kenanga - TP ranging from 2.71 to 3.07) did not include the visa-free scenario. All it takes is results from Q4'23 to justify another positive rerating.
As funds/institutions have high vested interest, I do not think it will be totally zero as it is used as a hedging tool; including the warrants issuer/market maker.
above is one of the key milestone in its recovery journey - May'24. Q4'23 performance will be interesting to watch and whether it will trigger another positive rerating. There's still 3 weeks to go before the end of window dressing :)
2.94 was its 52 weeks peak and that was before any solid recovery. now with 2 quarters of profits, it can't even recover to near its 52 weeks peak. not expecting it to be back to 2019 price instantly but can't even up to 2.94? that s purely suppression.
That's a one million dollar question, tim foo :) You probably have to make do with whatever information that is available. Let me give you an example: I think price near 2.6 or below can be considered assuming you are going to hold it for a min one year with min 15 cents dividend yearly. There's possibility of 9 cents div payout for FY23 still and another 15 cents in FY24. That makes it a cash flow of 24 cents dividend payout. Entry at 2.60 - 0.24 cents cash flow provided by the dividend means market price has to go below 2.36 before you start asking yourself the same question again - at which price should i add :) Just an example of how you can make do with assumptions and information available. Could be wrong and hope it helps :)
Understood where you are coming from after looking at the chart, Eddy. You are referring to the peak back in end of Jan'23 :) I believe it requires positive rerating - overweight or buy calls from analysts covering GenM in order for it continue higher. After all, the analysts are working for IBs and funds/institutions are the top30 shareholders :) If I may quote an example of Genting Singapore. It has close to 20 analysts coverage. It has recently gotten a few positive rerating (overweight) and hence, the market is moving in tandem to the positive rerating. Analysts covering Genting Singapore are probably covering Genting Malaysia and Genting Bhd too; may not be exactly the same number of analysts though. Perhaps the analysts are waiting for Q4'23 performance or the tourist arrivals numbers post visa-free before concluding their ratings; work in progress perhaps :)
Probably, Nick. After all, the downfall started with the 1.8bil impairment end of 2018, followed by the pandemic in 2020 to the bottom, followed by bear market rally to end of 2021 and entering consolidation until recently :)
Could be a translation error from my end, tim foo :) I read it as you want to add more but you dont know which position is better. Lol, thats the meaning of the translated wordings. Hence, I was giving an example of how you could use available information like min yearly dividend payout and what it meant if you were to add at 2.60. Considering the cash flow generated from dividend payout, market price has to go down below 2.36 before it starts affecting your investment at 2.60 negatively :)
Similar concept can be used for the positive side too :) Assuming you bought it at 2.60 and your intention is to sell at 3.0 and you have received 0.24 cents dividend, your investment will then generate ((3.0 - 2.60)+0.24) divided by 2.60 = 24.6%. It gives you an estimated rates of return that you wish to achieve based on available information. For me, i have been using a min 15% rates of return as the baseline. different individuals different rates of returns and its ok :)
those who invested back in 2019, 2020, 2021 and 2022 would be definitely impatient and disappointed in GenM. those who invested last two months of course can smile and tell others to be patient. it s all depends on your entry price and timeframe.
You can refer to the example that I mentioned on Genting Singapore and the importance of positive rerating, Eddy. The first link below showing the analysts overweight rerating for Genting Singapore while ratings for GenM is in the second link :) Hope this helps with your own research and please be reminded that this may not be the real time information.
I could not paste the second link for GenM as its detected as spam :) But you can use the search option on the top right corner to search for Genting Malaysia and click on the research and ratings tab.
Agreed, Mr K. positive external headwinds :) Global leisure and entertainment companies continued to rally higher, demand for air travel mostly back to pre-pandemic levels according to recent interview from IATA CEO, China which has just removed the group tour ban in stages this year is now at 80% of pre-pandemic level, international airlines group are optimistic with 2024 and expecting record number of travelers and revenues though constrained by limited capacity and high cost of capital :)
Net short positions looking really good, global leisure and entertainment companies continue with its rally higher, influx of economic data in the US that will give hints to possibility of rates cut to spur growth, and just in time for Dec window dressing.
You can find the information for net short positions as of the last trading day, tim foo. Eddy was asking the trend for the net short position for GenM :) Based on the latest updated figure as of 12th Dec and compared to the last two months data that I have downloaded, it is the lowest so far. Meaning - funds/institutions/warrant issuer/market makers have started to close the short positions. It will not be totally zero as it serves as a hedging tool.
We will know in two weeks time when the window dressing reaches its climax, Nick :) And followed by the usual quarter ending window dressing. so far so good and importantly, political stability :)
there is no objective evidence to support that it's an epidemic or pandemic, Tim Foo. It has been declared as endemic which means you will still see people falling sick :) Just like Influenza which is endemic, you will still get people infected or falling sick. I have seen some comments on the numbers :) Again, there is no objective evidence that it's something that should be concerned about at the moment. it's the same with the current seasonal flu during winter.
Perhaps speculation, Nick. The good thing with connectivity is that you can check for official information from WHO, CDC or FDA when it comes to risk of new novel pathogens. You can also check out any movements from the vaccine manufacturer like Pfizer or Moderna :)